Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response

Thomas Payen1, Paul E. Oberstein2, Niloufar Saharkhiz1, Carmine F. Palermo3,4, Stephen A. Sastra3,4, Yang Han1, Alireza Nabavizadeh1, Irina R. Sagalovskiy3,4, Barbara Orelli3,4, Vilma Rosario5, Deborah Desrouilleres6, Helen Remotti6, Michael D. Kluger3,5, Beth A. Schrope3,5, John A. Chabot3,5, Alina C. Iuga6, Elisa E. Konofagou1,3, and Kenneth P. Olive3,4

ABSTRACT

Purpose: Pancreatic ductal adenocarcinoma (PDA) is a common, deadly cancer that is challenging both to diagnose and to manage. Its hallmark is an expansive, desmoplastic stroma characterized by high mechanical stiffness. In this study, we sought to leverage this feature of PDA for two purposes: differential diagnosis and monitoring of response to treatment.

Experimental Design: Harmonic motion imaging (HMI) is a functional ultrasound technique that yields a quantitative relative measurement of stiffness suitable for comparisons between individuals and over time. We used HMI to quantify pancreatic stiffness in mouse models of pancreatitis and PDA as well as in a series of freshly resected human pancreatic cancer specimens.

Results: In mice, we learned that stiffness increased during progression from preneoplasia to adenocarcinoma and also effectively distinguished PDA from several forms of pancreatitis. In human specimens, the distinction of tumors versus adjacent pancreatitis or normal pancreas tissue was even more stark. Moreover, in both mice and humans, stiffness increased in proportion to tumor size, indicating that tuning of mechanical stiffness is an ongoing process during tumor progression. Finally, using a brca2-mutant mouse model of PDA that is sensitive to cisplatin, we found that tissue stiffness decreases when tumors respond successfully to chemotherapy. Consistent with this observation, we found that tumor tissues from patients who had undergone neoadjuvant therapy were less stiff than those of untreated patients.

Conclusions: These findings support further development of HMI for clinical applications in disease staging and treatment response assessment in PDA.

Introduction

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy with a median survival time of 6 months and a 5-year survival rate of just 8% (1). A pathognomonic feature of the disease is the deposition of an expansive, desmoplastic stroma that can comprise up to 90% of the tumor tissue. Stromal cells deposit and remodel profuse quantities of extracellular materials, forming a structured matrix that elevates interstitial fluid pressure, collapses tumor blood vessels, and obstructs tissue perfusion (2, 3). As a consequence, these tumors are pale and hard to the touch. This poor perfusion also contributes to the striking primary chemoresistance of pancreatic tumors, particularly to labile chemotherapeutic agents with a small therapeutic index (4). Multiple clinical trials are ongoing that target various elements of the PDA stroma as a means to improve drug delivery and, by extension, the efficacy of existing chemotherapies.

The diagnosis of PDA often follows a protracted period of diagnostic uncertainty. The earliest signs of pancreatic cancer are nonspecific, such as abdominal pain, gastrointestinal distress, and unexplained weight loss (5), and there is no sensitive and specific blood test yet available. The first definitive diagnostic evidence is typically either cross-sectional imaging, such as contrast CT or MRI, or endoscopic ultrasound (EUS), which offers a close view of the pancreas via an endoscope passed through the esophagus and into the stomach. However, even with state-of-the-art imaging, uncertainty often persists, particularly in discerning pancreatic cancer from mass-forming pancreatitis (6). Inflammation of the pancreas due to nonmalignant etiologies is a far more prevalent pathology than cancer and can share many features on imaging. Attempts to sample the tumor by EUS-guided biopsy hold the potential for a definitive diagnosis, but these have a high false negative rate due to the intricate association of PDA with adjacent inflammation (6). The differential diagnosis of PDA versus pancreatitis is clinically consequential; an unneeded intervention for cancer can exacerbate pancreatitis and diminish quality of life whereas the failure to resect a tumor can forestall the best opportunity to extend survival.

Given the distinct mechanical properties of PDA and the prominent role of ultrasound in the management of this disease, we sought to translate an ultrasound-based technique for the quantification of tissue stiffness for applications in differential diagnosis and disease monitoring in pancreatic cancer. Many existing techniques enable the imaging of tissue stiffness (elasticity imaging) by assessing the
**Translational Relevance**

Pancreatic ductal adenocarcinoma (PDA) is a deadly cancer that is challenging to diagnose, manage, and treat. Incipient pancreatic tumors can be difficult to distinguish from mass-forming pancreatitis, and once a patient is diagnosed and treatment begins, monitoring typically requires waiting months for changes in tumor size to become apparent by cross-sectional imaging. Harmonic motion imaging (HMI) provides a noninvasive, quantitative measure of relative tissue stiffness suitable for comparisons between individuals and over time. We effectively used HMI in both mouse models and human specimens to functionally distinguish pancreatic tumors from pancreatitis and delineate the margins of tumors otherwise not apparent with traditional ultrasound. Moreover, we learned that the mechanical properties of PDA mature during tumor growth, and that tumors responding to chemotherapy become softer in association to regression. These findings provide a translational rationale for the clinical implementation of HMI for pancreatic cancer.

perturbation of a tissue in response to an external, internal, or intrinsic mechanical stimulus. External perturbation techniques include quasi-static (7), transient (8), and dynamic elastography (9), as well as magnetic resonance elastography (MRE). These techniques are inherently compromised by signal attenuation and the complex interactions of the mechanical waves with different tissues, which lead to inaccurate measurements (10). Among the internal perturbation techniques, including vibroacoustography (11), shear wave elastography (SWE; ref. 12), and acoustic radiation force impulse imaging (13), most rely on a single ultrasound transducer to both produce a deformation and image the resulting displacement. Tissue nonlinearity, attenuation of the ultrasound propagation through tissue layers, and the power limits of imaging transducers place constraints on the acoustic radiation force that can be applied through an imaging transducer and by extension its sensitivity and depth of application (10). In addition, variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak.

Harmonic motion imaging (HMI) overcomes these limitations by separating the perturbation and imaging functions between two transducers. The first is dedicated to imparting a focused oscillation at depths over several centimeters within a tissue, thereby overcoming attenuation limitations; the high power output of the AM signal in HMI makes it possible to reach deep organs such as the pancreas and assess the wide variations in the speed of sound and respiratory motion can overshadow the perturbation if the latter is too weak. We previously demonstrated that HMI can generate two-dimensional (2D) elasticity maps of mouse abdominal organs and found that they accurately depict the relative stiffness of tissues (16). Most recently, we performed HMI on posturgical breast specimens and found that the technique is capable of mapping and differentiating stiffness in normal versus diseased samples (17). Most importantly, two groups have recently succeeded in engineering focused ultrasound transducers into an endoscope, enabling even greater access to internal organs such as the pancreas (18). Given the prominent role of EUS in the clinical diagnosis and management of pancreatic disease, these features indicate that HMI may be particularly well suited for applications in this setting. Here we examine the potential clinical utility of HMI using both genetically engineered mouse models of PDA and freshly resected human pancreatic cancer specimens. In mice, we test the hypothesis that stiffness can be used to distinguish PDA from genetically or chemically induced pancreatitis. In addition, we examine the association of tissue stiffness with murine pancreatic tumor growth and response to chemotherapy. These preclinical studies are then complemented with evidence from human patients by using HMI to measure tissue stiffness in a series of freshly resected PDA specimens. We assess the ability of HMI to distinguish areas of frank adenocarcinoma versus nearby normal and inflamed pancreas parenchyma and we evaluate the association of HMI-inferred stiffness with tumor size. Finally, we compare postsurgical specimens from patients who received neoadjuvant chemotherapy and/or chemoradiation therapy with those from untreated patients.

**Materials and Methods**

See Supplementary Information for additional details.

**B-mode ultrasound imaging**

Mice bearing nascent pancreatic tumors were initially identified using a Fuji Vevo 2100 high-resolution ultrasound with a 35-MHz transducer for mice housed within the animal barrier facility (Supplementary Fig. S1C). Subsequent anatomical imaging outside the barrier facility was performed using a Verasonics 18.5-MHz diagnostic probe (L22-14v).

**Harmonic motion imaging**

The acoustic radiation force was generated by a 93-element phased array transducer (H-178, Sonic Concept Inc.). An amplitude-modulated (AM) signal (frequencies: f\textsubscript{\textit{lower}} = 4.5 MHz and f\textsubscript{\textit{upper}} = 25 MHz) was sent by a dual-channel arbitrary waveform generator (AT33522A, Agilent Technologies Inc.) to drive all 93 channels (325LA, E&I). The resulting beam induced a 50-Hz harmonic tissue oscillatory motion at the transducer focus. A calibration performed in water showed that the acoustic power produced by this system was 5.04 W. Further details on the HMI system are provided in the study by Hou and colleagues (19).

A Vantage 256 system (Verasonics) was used to operate the imaging probe in a plane-wave beam sequence with a frame rate of 1 kHz. Two different phased arrays from ATL/Philips were used. For mouse experiments, the RF acquisition was performed using a P12-5 probe (104 elements, aperture = 12 mm, center frequency f\textsubscript{c} = 7.5 MHz) for higher resolution. In the case of human specimens, higher penetration and field of view were obtained with a P4-2 phased array (64 elements, aperture = 20 mm, f\textsubscript{c} = 2.5 MHz). Raster scans were performed by mechanically moving the transducer using a three-dimensional (3D) positioning system (Velnex Inc.) in a raster scan format. At each
position, the tissue was mechanically oscillated for 0.2 second, during which 200 channel data frames (10 oscillation cycles) were acquired using a plane wave imaging sequence. Delay-and-sum beam forming using Graphics Processing Unit (GPU)-based sparse-matrix operation (20) was then performed to reconstruct the RF frames. The focused ultrasound (FUS) fundamental frequency and its harmonics were then filtered out of the RF frames to remove any noise interference between the two ultrasound beams.

**HMI displacement estimation**

The incremental displacement along the axis of ultrasound transmission was estimated using a one-dimensional (1D) cross-correlation function (21) along each beam line. A band-pass filter around the displacement frequency (50 Hz) was applied to further reduce noise. The median peak-to-peak displacement amplitude was estimated at each pixel.

To reconstruct the entire imaging plane, attenuation was compensated by $D_z = D_{z0}e^{D(z_0 - z)/\alpha}$, where $D_{z0}$ and $D_z$ are the displacements measured at depth $z$ and at the focal depth $z_0$, $f$ is the imaging frequency, and $\alpha$ is the attenuation coefficient fixed at 0.5 dB cm$^{-1}$ MHz$^{-1}$.

For each 2D imaging plane, a region of interest was manually segmented on the B-mode acquired with the imaging probe (Supplementary Fig. S1C). The HMI values presented in this work are mean values ± standard deviation. Two-tailed $t$ tests with a threshold $P$ value of 0.05 were used to determine the significance of the difference.

**Mouse models**

All animal procedures were reviewed and approved by the Columbia University Irving Medical Center (CUIMC) Institutional Animal Care and Use Committee. All the animals were anesthetized with 1% to 2% isoflurane in oxygen throughout the imaging procedures. Mice were placed in supine position on a heating pad with their abdomen depilated. A container filled with degassed water was placed with an acoustically transparent window above their abdomen and coupled with degassed ultrasound gel.

Five different types of mice were used in this study. Wild-type (WT) BalbC mice (WT mice, $N = 32$) were used as normal controls. K-ras$^{LSLG12D/+}$; PdxCre$^{GR+/+}$ mice (KC mice, $N = 24$) that spontaneously develop pancreatic and pancreatic intraepithelial neoplasia (PanIN) lesions, a microscopic precursor of PDA (22). K-ras$^{LSLG12D/+}$; p53$^{R172H/+}$; PdxCre$^{GR+/+}$ (KPC mice, $N = 30$) develop autochthonous PDAs with pathophysiological and molecular features resembling human PDA (4). Tumor development in the KPC model is readily visualized using very high-resolution (35 MHz) B-mode ultrasound (Supplementary Fig. S1C), with normal pancreatic tissue appearing homogeneously hyperechoic (bright) and inflamed/premalignant pancreas becoming progressively more mottled and heterogeneous (23). Nasal pancreatic tumors are apparent as a solid, hypoechoic mass as small as 2-mm diameter (23). However, 35-MHz ultrasound imaging cannot be applied clinically because this high frequency of ultrasound required can penetrate only up to approximately 1 cm into tissues. K-ras$^{LSLG12D/+}$; p53$^{R172H/+}$; PdxCre$^{GR+/+}$; Brcal$^{flox/flox}$ (KPCB$^{+/+}$ mice, $N = 8$) rapidly develop Brcal-deficient pancreatic tumors (24). Elastase-II-ILβ transgenic mice (Ela-IL1β mice, $N = 8$) express the inflammatory cytokine IL-1β from the acinar cell-specific elastase gene, resulting in chronic pancreatitis with inflammatory infiltrate and local edema, but minimal extracellular matrix (ECM) deposition (25).

Additional details are presented in supplementary methods.

**Harmonic Motion Imaging of Pancreatic Cancer**

**Table 1. Patient characteristics.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age</td>
<td>71.2 years</td>
</tr>
<tr>
<td>Range (years)</td>
<td>58–95</td>
</tr>
<tr>
<td>Gender</td>
<td>Female 54% (7/13), Male 46% (6/13)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neoadjuvant therapy (NAT)</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>54% (7/13)</td>
</tr>
<tr>
<td>Some</td>
<td>46% (6/13)</td>
</tr>
<tr>
<td>Duration of NAT</td>
<td>254 days (189–369)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of surgery</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distal pancreatectomy</td>
<td>46% (6/13)</td>
</tr>
</tbody>
</table>

**Pancreatitis induction**

The secretory peptide cerulein was administered in some experiments to induce or exacerbate pancreatitis. Short-term treatment of WT mice with cerulein induces a mild, acute pancreatitis that lacks ECM deposition. By contrast, treatment of KC mice with cerulein intensifies their basal pancreatitis phenotype, producing an exuberant inflammatory reaction with substantial desmoplasia (26). We treated 10 WT mice and 14 tumor-free KC mice with intraperitoneal injections of cerulein (250 mg kg$^{-1}$) daily for 5 days (27). Mice were imaged 1 week after induction.

**Human tissue specimens**

All work with clinical specimens was performed in accordance with the guidelines of the Belmont report and following human subjects protocol approval by the CUIMC Institutional Review Board (IRB#AAAP0401). Informed consent was obtained from all enrolled subjects. A total of 13 tissue specimens were obtained after distal pancreatectomy ($N = 6$) or a Whipple procedure ($N = 7$). Patient characteristics are provided in Table 1. Following resection and margin evaluation by surgical pathology, the specimens were transported to the laboratory in sterile saline for up to 90 minutes of specimen preparation and ultrasound setup and imaging and then returned to pathology for standard evaluation. All tumors were PDA. The age range of the patients was 58 to 95 years (average age: 71.2 ± 9.7 years). The pancreatic specimens used for the experiments had an average size of 13 × 5 × 3 cm$^3$. Specimens were immersed in degassed PBS in a water tank with a layer of sound-absorbing material at the bottom to limit undesired echoes from the tank. Plastic wrap was placed on top of the specimen and pinned to the bottom to keep it from floating to the surface.

The specimens were oriented so that the imaging probe was perpendicular to the pancreatic duct to correlate with histology slicing. For each tissue, two harmonic motion scans were performed. Scan 1 probed the maximal 2D cross section of the tumor as detected using palpation and B-mode images acquired with the 2.5-MHz probe. Scan 2 was performed in 3D as a succession of imaging planes along the pancreatic duct from the surgical margin to the opposite end of the pancreas.

The sampling of the human specimens was performed by a dedicated pathology assistant with expertise in pancreatic resection specimens. The histologic features of the human pancreatectomy specimens were reviewed by a gastrointestinal pathologist. A preplanned safety stop was implemented after the first 3 patients to confirm that the procedures did not impact diagnostic utility of the specimens; no evidence of any pathologic changes was noted in HMI insonicated samples. Representative tumor sections as well as adjacent

---

*Published OnlineFirst December 12, 2019; DOI: 10.1158/1078-0432.CCR-18-3669*
nonneoplastic pancreas with or without pancreatitis were selected for Sirius red and trichrome staining.

Statistical analyses
Statistical analyses were performed using GraphPad Prism v8.1.2 software. Pairwise comparisons were assessed using an unpaired, two-tailed Student's t test. Multiple comparisons were made using an ordinary one-way analysis of variance with Tukey multiple comparison's test for specific comparisons, as indicated in the figure legends. Summary values are presented as mean ± standard deviation. Correlation shown in Fig. 1D utilized a one-phase exponential decay; other correlations used linear regression, with $R^2$ values indicating goodness of fit.

Results
Stiffness increases during pancreatic tumor development and progression
To assess the stiffness of normal, preinvasive, and malignant pancreatic tissues, we made use of the KPC genetically engineered mouse, a well-validated and clinically predictive genetically engineered model of PDA (4, 22). Using HMI, we measured the displacement of normal pancreas tissue in WT mice as well as pancreatic tissues from KPC mice with PanINs or PDA. $P$ values are indicated using a one-way ANOVA and Tukey multiple comparisons test. C, Quantification of picrosirius red (PSR) birefringence in pancreatic tissue sections. D, Displacement as a function of picrosirius red (PSR) density for the three groups displaying one-phase exponential decay (black line). Only animals that did not receive additional treatments prior to necropsy are shown.
Pancreatic stiffness increases with disease progression. A, Longitudinal HMI displacement maps of a KPC mouse (K8741) showing increased stiffness over the course of 20 days of tumor growth. Bars = 2 mm. B, Quantification of tissue stiffness from six KPC mice demonstrates a consistent decrease in stiffness over time following tumor initiation. C, The stiffness of each tumor from B is strongly inversely correlated with tumor size (mean $R^2 = 0.78$). D, Representative HMI displacement maps, H&E, and picrosirius images of pancreatic tissues from four models of pancreatitis: wild-type mice treated with cerulein (WT + Cer), Elastase-interleukin 1β transgenic mice (IL1β), Kras$^{LSL.G12D/}$; Pdx1-Cre$^{ERT2}$ (KC) mice, and KC mice treated with cerulein (KC + Cer). Bars = 2 mm for HMI maps, 200 μm for H&E, and 40 μm for picrosirius images. E, Stiffness was significantly increased in the pancreata of KC mice treated with cerulein, but all pancreatitis models were significantly less stiff than KPC pancreatic tumors. Selected statistical comparisons shown using a one-way ANOVA and Tukey multiple comparisons test between all groups. F, Quantification of picrosirius red staining found increased collagen deposition in KPC tumors versus all other groups (one-way ANOVA + Tukey’s range statistical test (Tukey) between all groups). IL1β, KC, and KC + cer mice had modestly elevated collagen deposition, but this was not statistically significant after multiple hypothesis correction.
However, pancreatic tumors were starkly apparent on HMI displacement maps based on their increased stiffness (lower displacement) relative to surrounding tissues (Fig. 1A). Quantification of mean displacement clearly demonstrated significantly increased stiffness between WT, PanIN, and PDA tissues, with displacements of 12.57 ± 1.58 μm, 9.90 ± 1.60 μm, and 4.04 ± 1.01 μm, respectively (Fig. 1B, P < 0.0001; Tukey’s for WT vs. PDA). The severe desmoplasmatic changes associated with tumor progression were clearly apparent both by routine hematoxylin and eosin staining and by picrosirius red birefringence, a stain that enables the quantitative measurement of ordered collagen content. Indeed, PDA tissues also exhibited significantly higher collagen content than PanIN tissues (37.78 ± 16.46% vs. 11.86 ± 16.77%, Fig. 1C, P = 0.0012, Tukey), and collagen content broadly correlated with tissue stiffness across all samples (Fig. 1D, R² = 0.64, one-phase exponential decay).

We next sought to understand how tissue stiffness is altered during the transition from premalignancy to adenocarcinoma. We used high-resolution (35 MHz) b-mode imaging to identify KPC mice with nascent tumors and then analyzed tissue stiffness of the tumors over time using HMI (Fig. 2A and B). We found that stiffness increased during PDA growth, beginning at an average displacement of 6.8 ± 1.25 μm, slightly lower than PanIN samples (P = 0.004, unpaired t test) and decreasing to 3.86 ± 1.24 μm at endpoint (P = 0.0056 vs. initial values, paired t test). Within each animal, displacement was inversely correlated with tumor size, with an average slope of −0.91 μm/mm (Fig. 2C, P = 0.0004 vs. 0 slope by one-sample t test, mean R² = 0.77). We considered the possibility that this observation reflected a general relationship between object size and displacement as measured by HMI and assessed this by performing HMI on a calibrated phantom with a stiff stepped-cylinder inclusion embedded within a soft matrix (Supplementary Fig. S2). Harmonic motion scans performed on the 6.5-mm and 10-mm diameter sections exhibited mean HMI displacements of 3.45 ± 1.25 μm and 3.75 ± 2.41 μm, respectively, disproving a geometry dependence of the HMI technique in measuring stiffness of different sized objects beyond a certain size. Together, these findings indicate that pancreatic tumor stiffness increases during tumor progression.

**HMI stiffness distinguishes pancreatitis from pancreatic cancer**

To evaluate the utility of HMI for distinguishing pancreatitis from PDA, we assessed several pancreatitis conditions in four mouse models of pancreaticitis: WT mice treated with cerulein (mild acute pancreatitis), Ela-II.1b transgenic mice (mild chronic pancreatitis), KC mice (moderate chronic pancreatitis), and KC mice treated with cerulean (severe chronic pancreatitis; Fig. 2D and E, see “Materials and Methods” for additional details). Pancreatic tissue displacement measurements made in most of these disease models were not significantly different than that of normal pancreatic tissue (12.57 ± 1.58 μm for WT vs. 13.14 ± 3.80 μm for WT + cer, 13.64 ± 4.03 μm for Ela-II-1b, and 13.05 ± 3.23 μm for KC, all comparisons not significant). However, cerulein-treated KC mice with severe chronic pancreatitis had significantly increased pancreatic stiffness (7.20 ± 1.69 μm) compared with WT pancreas tissue (P = 3.2 × 10⁻⁴, Tukey). Of note, this change was not accompanied by an increase in picrosirius red staining, perhaps indicating a difference in the structure of collagen in the ECM of pancreatitis in this model compared with PDA (Fig. 2F). Consistent with this, the mean HMI displacement of KPC pancreatic tumors (4.04 ± 1.01 μm) was significantly lower than chronic pancreatitis in the cerulein–treated KC mice (P = 0.0011, Tukey). These results further support the potential for HMI to distinguish PDA from nonmalignant pathologies.

**HMI detects changes in stiffness in response to therapeutic intervention**

To assess the ability of HMI to detect therapy-induced changes in tissue stiffness, we made use of a BRCA2–deficient model of PDA. Our group has found that most KrasSL-G12D+/−; p53LSL.R270H+/+; PdxCreE7−/−; brca2F/F (KPCB2/F) tumors are sensitive to treatment with the DNA cross-linking agent cisplatin, inducing residual acellular lacunae following the apoptotic loss of tumor cells (Fig. 3A and B). This model provides the opportunity to study successful chemotherapeutic responses in a disease that is otherwise highly chemoresistant. Using high-resolution conventional ultrasound, we identified KPCB2/F mice with nascent tumors and monitored both tumor size and stiffness longitudinally by HMI during treatment with cisplatin (Fig. 3C). A tumor from a KPCB2/F mouse treated with vehicle exhibited increased tumor stiffness over time, similar to our observations in the KPC model (Supplementary Fig. S3A). In contrast, 7 KPCB2/F mice treated with cisplatin all survived at least twice as long as the vehicle-treated animal. Analysis of tumor volumes showed evidence of disease stabilizations or frank regressions in cisplatin-treated tumors and these were generally accompanied by increased displacement as measured by HMI (Fig. 3D and E; Supplementary Fig. S3B–S3H). To quantitatively assess this relationship, we segmented the growth curves of each cisplatin-treated KPCB2/F tumors into groups characterized as “progressing” or “responding” (Supplementary Fig. S3). Notably, the change in HMI displacement of responding segments (0.093 ± 0.119) was significantly higher than progressing segments (−0.054 ± 0.103; Fig. 3F and G, P = 0.028, unpaired t test), potentially indicating that successful response to chemotherapy is associated with reduced tumor stiffness. These data suggest that HMI may prove useful as an early indicator of response to treatment in patients with pancreatic cancer, particularly in the metastatic setting where liver or other distant metastases may be accessible by noninvasive, extracorporeal ultrasound.

**Clinical evaluation of HMI in freshly resected pancreatic cancer specimens**

In light of the promising preclinical results using HMI on mouse models of PDA, we established a clinical protocol to perform HMI on intact, freshly resected pancreatic specimens from patients with PDA (see Table 1 for patient characteristics). For each case, multiple B-mode and HMI images were acquired at successive steps through the specimen in an orientation consistent with standard pathology procedures such that a rough coregistration of imaging and histopathology could be performed (Fig. 4A and B). Notably, in 7 of 13 cases, the anatomical border of tumor within the overall pancreas specimen was difficult or impossible to delineate by 2.5-MHz B-mode ultrasound, even under these ideal ex vivo conditions (Fig. 4C). By comparison, we found that tumor tissues were starkly apparent by HMI (Fig. 4D). To quantify this distinction, we selected harmonic motion scans either from within the malignant mass, proximal to the tumor, or at a distance from the tumor, roughly aligning with regions of PDA, adjacent inflamed tissues, or mostly normal tissues, as determined by histopathologic assessment of associated tissue blocks. Notably, HMI displacement in regions of adenocarcinoma was nearly 7-fold lower than in normal pancreas (Fig. 4B, 2.30 ± 1.36 μm vs. 16.07 ± 2.51 μm, respectively, P < 1 × 10⁻⁵, Tukey), substantially larger than the approximately 3-fold difference observed in mice (Fig. 1). In addition, we also observed lower displacement within the tumor compared with adjacent pancreatitis (12.34 ± 2.34 μm, P < 1 × 10⁻⁵, Tukey). Interestingly, clear delineation of tumor margins was apparent by HMI despite histopathologic evidence of extensive pancreaticitis in the regions directly adjacent to tumors (Fig. 4E–K). The ability of HMI to
distinguish tumors from adjacent, inflamed pancreatic tissues (Fig. 4L) due to the collagen density change (Fig. 4M) supports its potential utilization for the differential diagnosis of pancreatitis versus PDA.

We next examined the relationship between tumor size and stiffness. We found that, consistent with our preclinical data, larger pancreatic tumors generally had a lower displacement than smaller tumors (Fig. 5A; slope = -0.013 μm/mm², R² = 0.26, P = 0.08) indicating a borderline association between tumor stiffness and progression. Furthermore, in the course of examining the tumor size/stiffness data, we noted a potential impact of neoadjuvant treatment status (Fig. 5C). A formal assessment of the impact of chemotherapy on tissue stiffness would require longitudinal imaging of patients as they were treated with chemotherapy. Although this was not possible under the current ex vivo protocol (performed at endpoint on resection specimens), we made use of the fact that a subset of the patients in this study received neoadjuvant chemotherapy or chemoradiotherapy (Supplementary Table S1), including gemcitabine/nab-paclitaxel (GA), gemcitabine/docetaxel/capecitabine (GTX), or 5-fluorouracil/irinotecan/leukovorin/oxaliplatin (FOLFIRINOX), alone or in combination with stereotactic or intensity-modulated radiotherapy. Neoadjuvant therapy is used to induce acute regression in order to downstage tumors to a sufficient degree to enable resection, with treatment generally continuing until several weeks before surgery. Among the 13 patients in our cohort, 6 underwent some form of neoadjuvant therapy prior to resection and therefore may be considered to have responded sufficiently to enable surgery. We therefore assessed the relationship between tumor stiffness and treatment status. Consistent with our preclinical results, neoadjuvant-treated human pancreatic tumors exhibited a significantly lower stiffness than untreated tumors (displacement = 3.35 ± 1.30 μm vs. 1.40 ± 0.48 μm, respectively, Fig. 5D and E, P = 0.0035, unpaired t test). Although these differences may reflect preexisting distinctions between the population of patients who are candidates for immediate resection...

Figure 3.
Pancreatic tumor stiffness is altered by therapeutic intervention. A and B, H&E histopathology images from two KPCB2/F/F pancreatic tumors treated either with saline (A) or with cisplatin. Bars = 200 μm. C, Experimental design for therapeutic study of KPCB2/F/F mice. Tumor-bearing mice were identified by high-resolution ultrasound and then treated with 3 mg/kg cisplatin, intravenously, once weekly for 3 weeks, followed by a 1-week rest cycle. This 4-week cycle was repeated with longitudinal HMI until mice met endpoint criteria. D, HMI displacement maps for a KPCB2/F/F mouse treated with cisplatin (B2499) over time. Bars = 2 mm. E, Longitudinal tumor volume and HMI displacement measurements of Mouse B2499. Red curve indicates tumor volume, blue curve indicates tumor HMI displacement. Dotted lines indicate dates of cisplatin treatment. F and G, Quantification of tumor growth slopes and displacement slopes, respectively, for progressing and responding curve segments as delineated in Supplementary Fig. S3, compared using Student t test.
Figure 4.
Elevated tissue stiffness in human PDA. A, Photograph of a distal pancreatectomy specimen. Hashed white oval indicates position of a pancreatic ductal adenocarcinoma. Yellow lines indicate imaging planes. B, HMI displacement map from scan 17 in A showing that the mostly normal pancreas tissue (labeled P) distal to the tumor is soft (blue color). C and D, B-mode (C) and HMI displacement images (D) from scan 1 in A, depicting the main mass of the pancreatic tumor (labeled T). Notably, the borders of the tumor in the B-mode image are indistinct, in comparison, the HMI maps clearly distinguish the extent of disease. Microscopic images of the sample from A, showing normal pancreas uninvolved with tumor (E–G) compared with the center of the adenocarcinoma mass (H–J). Tissue sections are stained with H&E (E and H, bars = 200 μm), Masson trichrome (F and I, bars = 200 μm), or picrosirius red (G and J, bars = 40 μm). PDA images show evidence of the extensive extracellular matrix deposition that is characteristic of pathology of pancreatic cancer and contribute to increased stiffness. K, A 3D rendering of the resection specimen from A, using HMI results from scans 2 to 17, clearly indicates the location of the tumor. Bar = 25 mm. L, Quantification of tissue displacement for 13 human PDA specimens (PDA) compared with adjacent inflamed pancreas (Adj) or largely normal pancreas tissue (Norm), when present. Pancreatic tumor tissue was significantly more stiff than inflamed or normal pancreatic tissue (one-way ANOVA + Tukey). M, Quantification of picrosirius red staining on samples from 12 PDA specimens showing increased collagen deposition in PDA versus adjacent inflamed or normal pancreatic tissue (one-way ANOVA + Tukey).
Figure 5.
Stiffness of human PDA varies with tumor size and treatment. A and B, HMI displacement maps from a small (B) and a large (C) pancreatic tumor showing increased stiffness in the larger tumor. C, Quantification of 13 PDA resection cases found that tumor size (based on 2D area) was inversely correlated with HMI displacement (by linear regression). Red dots indicate tumors with no prior therapy ($R^2 = 0.36$); blue dots indicate tumors that received neoadjuvant therapy ($R^2 = 0.57$). Black line indicates regression of all samples ($R^2 = 0.26$). D, HMI displacement maps in tumor (left) and normal pancreatic parenchyma (right) from a human specimen with no prior therapy (top) and a tumor that received 3 months of gemcitabine + Abraxane and intensity-modulated radiotherapy. E, Comparison of HMI displacement between untreated and treated specimens, examining PDA, adjacent inflamed pancreas, and distal normal pancreas. The stiffness of PDA decreased after treatment while the stiffness of normal tissue increased (Student t test for each pairwise comparison). F, Microscopic images of the specimens from D, showing both tumor and normal pancreatic tissues stained with H&E or Masson trichrome. Bars, 200 μm.
and those who required neoadjuvant therapy in order to achieve resection, the two groups had similar tumor grades and there was no statistical difference in the number of positive evaluated lymph nodes between the groups ($P = 0.75$, Fisher exact test). These data may therefore reflect the ability of HMI to detect reduced tissue stiffness in response to neoadjuvant therapy–induced tumor responses. On the other hand, we noted that normal pancreatic parenchyma from neoadjuvant-treated patients exhibited increased stiffness compared with untreated patients (displacement $= 17.66 \pm 2.26 \mu m$ vs. $14.22 \pm 1.16 \mu m$, respectively (Fig. 5E, $P = 0.0066$, Student’s $t$ test), perhaps due to chemotherapy/radiation–induced fibrosis in the normal pancreas (Fig. 5F). Together, our findings support the potential use of HMI as a candidate modality to both clarify differential diagnoses and monitor early responses to therapy.

Discussion

Pancreatic surgeons often describe PDA as feeling hard or even “rock-like.” Such anecdotal accounts inspired our effort to derive a clinically useful means to measure and quantify tissue stiffness in pancreatic cancer. In PDA, this gross mechanical property arises from the combined effects of several biological features of the epithelial and stromal compartments. K-ras and other oncogenic driver proteins induce cytoskeletal changes in malignant epithelial cells via downstream effectors such as PI3K and Rac (28). K-ras also induces a host of paracrine signals that control the cellular composition of the tumor stroma, promoting the activation of stromal cells that deposit and remodel the ECM (29). Stromal cells secrete polymeric proteins such as collagen; carbohydrate polymers such as glycosaminoglycans and heparin sulfate; proteoglycans; and matrix remodeling enzymes that confer high mechanical stiffness as well as high interstitial fluid pressure, via trapping of water into a hydrogel (30). The net effect is an environment with such high pressure and stiffness that many smaller blood vessels are collapsed, leading to poor perfusion and compromised drug delivery (4). Using HMI, we were able to detect increased stiffness in pancreatic tumor samples in both mice and humans; indeed, in human resection samples, the demarcation between tumor and adjacent tissue by HMI was particularly apparent, far exceeding the contrast from standard anatomical ultrasound, even when B-mode imaging was unable to delineate the tumor. The strong performance of HMI in this side-by-side comparison both supports the utilization of HMI to aid in differential diagnoses and also raises the possibility that HMI could help guide the placement of biopsy needles during routine EUS-guided biopsy procedures.

A key finding was that HMI was capable of distinguishing PDA from pancreatitis across a range of murine models, as well as in human pancreatic resection samples (relative to adjacent inflamed tissues). Pancreatitis denotes a diverse range of inflammatory pathologies of the pancreas, including both acute and chronic manifestations, arising from a variety of genetic, autoimmune, chemical, and environmental insults. Pancreatic inflammation from both malignant and nonmalignant etiologies can produce similar features on standard imaging; we establish here that the former results in a higher range of stiffness values by HMI than pancreatitis samples in both mice and humans, serving as a potential basis for quantitative distinction of these states. This concept has also been explored using MRE (31) and other technologies (32, 33), though subject to the technical limitations and ease of quantification noted earlier. The mechanistic basis for this distinction is not completely clear but may be related to the organization of ECM components such as collagen that can develop during the process of malignancy (34) and is negatively associated with the outcome of patient with pancreatic cancer (35). This concept is supported by our observation that stiffness continues increase over time in murine pancreatic tumors, implying an ongoing process of stromal maturation that is reflected in the mechanical properties of tumors.

One of the major clinical challenges of treating patients with metastatic pancreatic cancer is that there is typically only time to attempt one or two therapeutic interventions before the patient’s condition deteriorates. This can be further exacerbated by the extended time between when a patient is first treated and when a clinical response, or progression, may be detected by anatomical imaging. A noninvasive means of detecting the response of tumors early in a treatment course could provide an invaluable opportunity to assess additional regimens. The biomechanical properties of pancreatic cancers can be altered in response to chemotherapy by directly altering the viscoelastic properties of tumor cells (36), through indirect effects on the tumor micro-environment (37), or through tissue decompression following the apoptotic loss of cells. For example, ultrasound elastography was previously utilized to detect decreased stiffness in response to gemcitabine + nab-paclitaxel treatment in human patients with PDA, an effect that was associated with disorganization of collagen structure and loss of stromal fibroblasts (38). A similar effect was noted using SWE in patients with rectal cancer treated with high-dose chemoradiotherapy (39) and in patients with breast cancer following neoadjuvant therapy (40, 41). Consistent with these findings, we found that HMI can detect changes in tissue stiffness over the course of just a few days in a chemo-sensitive genetically engineered mouse model, following treatment with cisplatin. These changes were associated with an apoptotic response that led to a loss of cellular content that we infer decompressed the tissue, though effects on cell stiffness and ECM content could also play a role. Critically, our findings were supported by clinical observations that pancreatic tumors from patients with PDA who received neoadjuvant chemotherapy or chemoradiotherapy had a lower mean relative stiffness than treatment-naïve tumors (Fig. 5E).

To be clear, this clinical comparison is confounded by the fact that these two groups draw from different patient populations. However, patients who require neoadjuvant therapy, by definition, have progressed further than those who can proceed directly to resection, and therefore their tumors would be expected to be larger and stiffer. That their tumors were in fact less stiff is consistent with the interpretation that neoadjuvant therapy caused softening of the tumor. Nonetheless, a definitive determination on HMI potential for neoadjuvant response evaluation will require longitudinal studies in patients, either through extracorporeal assessment of metastatic lesions or using HMI–equipped endoscopy. Such longitudinal studies will also be critical to establish whether quantifiable changes in tissue stiffness actually precede changes in tumor size or growth rate, establishing the basis for an early biomarker of therapeutic response.

To our knowledge, an association between neoadjuvant therapy and tissue stiffness in normal pancreatic tissues has not been previously reported. Although preliminary, this finding highlights a key advantage of HMI over other clinically available forms of elasticity imaging that rely on contrast to surrounding pancreas tissues to facilitate tumor monitoring. The opposing effects of neoadjuvant therapy on tumor versus normal pancreas tissue serve to diminish the inherent contrast of PDA versus surrounding tissues, potentially masking the presence of residual disease in treated patients. The ability of HMI to provide a quantitative displacement measurement for tumor tissues without relying on adjacent control tissues provides a more direct path for clinical implementation.

Published OnlineFirst December 12, 2019; DOI: 10.1158/1078-0432.CCR-18-3669
In summary, we envision several clinical applications for HMI in the setting of pancreatic cancer. With the incorporation of HMI into a GI endoscope, HMI may be deployed as a key component of routine diagnostic scans of the pancreas, providing critical, complementary information to B-mode ultrasound for challenging cases. With the same instrument, HMI may also prove useful for guiding biopsy needle placement and longitudinal monitoring of disease progression. Finally, for patients with metastatic cancer, many liver and other lesions will be accessible by transabdominal HMI, enabling routine imaging and quantification of early response to therapeutic intervention. Thus, this work provides an essential translational foundation for diverse applications of HMI in patients with PDA.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: T. Payen, P.E. Oberstein, J.A. Chabot, E.E. Konofagou, K.P. Olive
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Payen, P.E. Oberstein, N. Saharkhiz, C.F. Palermo, S.A. Sastra, Y. Han, A. Nabavizadeh, I.R. Sagalovskiy, B. Orelli, V. Rosario, H. Remotti, M.D. Kluger, B.A. Schroepe, J.A. Chabot, A.C. Iuga, E.E. Konofagou, K.P. Olive
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Payen, N. Saharkhiz, C.F. Palermo, L.R. Sagalovskiy, H. Remotti, K.P. Olive
Writing, review, and/or revision of the manuscript: T. Payen, P.E. Oberstein, I.R. Sagalovskiy, M.D. Kluger, B.A. Schroepe, J.A. Chabot, E.E. Konofagou, K.P. Olive
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Payen, N. Saharkhiz, V. Rosario, D. Desvauchelles, A.C. Iuga, E.E. Konofagou, K.P. Olive
Study supervision: T. Payen, V. Rosario, E.E. Konofagou, K.P. Olive

Acknowledgments
K.P. Olive received support for this work from the Lustgarten Foundation for Pancreatic Cancer Research. The NIH provided support in part to E.E. Konofagou (R01 CA228275) and P.E. Oberstein (KL2 TR000081). The authors thank Timothy Wang for donating the Elastase-IIIβ transgenic mice. This work was supported by the Herbert Irving Comprehensive Cancer Center CCSG grant (NIH/NCI P30 CA13696), in particular the Molecular Pathology Shared Resource, the Oncology Precision Therapeutics and Imaging Shared Resource, and the Database Shared Resource. Finally, the authors thank Hanina Hibshoosh for advice and guidance.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 12, 2018; revised May 3, 2019; accepted December 5, 2019; published first December 12, 2019.

References


